SecBot SecBot

SLNO

SOLENO THERAPEUTICS INC
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001484565 Biotech & Drug Discovery
No price
Median target
$53.00
range $53.00–53.00
Short interest
4.41M
−32.5%
Days to cover
2.3
at average volume
Insider net
$0
no open-market trades · since May 18
New fund stakes
0
Q2 2026 13F · 26 exits
Filing reports
10
analyzed by SecBot
SecBot read MIXED 5 reports · latest
Balance 2 bearish · 2 bullish · 1 mixed oldest → newest, height = score
Avg score ·High conf. 3/5

Price

Daily candles with volume.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells since May 18. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBEARISH

    Q2 2026: 0 added (0 new), 26 trimmed or exited.

  • EstimatesFALLING

    Current-quarter EPS estimate $0.980 → $0.934 over 90 days. 0 up, 3 down in 30 days.

  • Short sellersCOVERING

    Short interest −32.5% to 4.41M shares. 2.3 days to cover.

Who's buying

13F· Q2 2026
0
new positions
26
exits

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action Apr 2026
Recent actions
DateFirmActionRating
Apr 17, 2026Wells Fargo
DOWNGRADE
DOWNGRADEEqual-Weight
Apr 8, 2026HC Wainwright & Co.
DOWNGRADE
DOWNGRADENeutral
Apr 7, 2026TD Cowen
DOWNGRADE
DOWNGRADEHold
Apr 7, 2026Wolfe Research
DOWNGRADE
DOWNGRADEPeer Perform
Apr 6, 2026Cantor Fitzgerald
DOWNGRADE
DOWNGRADENeutral
Mar 18, 2026Oppenheimer
MAINTAIN
MAINTAINOutperform

Insider ledger

Form 4
$0
open-market buys or sells · since May 18
DateInsiderTypeValue
May 18, 2026
Anish Bhatnagar
CHIEF EXECUTIVE OFFICER
May 18, 2026
TO ISSUER131,400 sh
May 18, 2026
Anish Bhatnagar
CHIEF EXECUTIVE OFFICER
May 18, 2026
TO ISSUER115,600 sh
May 18, 2026
Anish Bhatnagar
CHIEF EXECUTIVE OFFICER
May 18, 2026
TO ISSUER100,000 sh
May 18, 2026
Anish Bhatnagar
CHIEF EXECUTIVE OFFICER
May 18, 2026
TO ISSUER200,753 sh
May 18, 2026
Anish Bhatnagar
CHIEF EXECUTIVE OFFICER
May 18, 2026
TO ISSUER52,709 sh
May 18, 2026
Anish Bhatnagar
CHIEF EXECUTIVE OFFICER
May 18, 2026
TO ISSUER73,333 sh
May 18, 2026
Anish Bhatnagar
CHIEF EXECUTIVE OFFICER
May 18, 2026
TO ISSUER8,473 sh
May 18, 2026
Anish Bhatnagar
CHIEF EXECUTIVE OFFICER
May 18, 2026
TO ISSUER35,000 sh

Earnings setup

Estimates
$0.93
EPS estimate, this quarter
−5%
estimate change, 90 days
0↑ 3↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Next Q$1.06$0.78–$1.55+0.0%$122.9M
Current Q$0.93$0.78–$1.26-0.4%$111.8M
Next FY$6.06$3.61–$9.92-3.6%$670.5M
Current FY$3.89$2.69–$5.55-1.4%$464.3M

Washington

Corporate Lobbying

13 lobbying filings and 12 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· May 15, 2026
4,405,832
shares short
-32.5%
vs prior settlement
2.3
days to cover
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Sep 2, 2026 Other
Kuehn Law Encourages Investors of Soleno Therapeutics, Inc. to Contact Law Firm
NEW YORK, Sept. 2, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is inves
Jun 30, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC · EXIT
0 shares ($0.00)
Jun 30, 2026 Inst.
FMR LLC · EXIT
0 shares ($0.00)
Jun 11, 2026 SEC
15 institutional investors accumulated positions in SLNO during Q3 2024, with Pictet Asset Management ($29.1M) and…
INST-CLUSTER · Impact 6/10
Jun 11, 2026 SEC
Six institutional investors accumulated $883.9M in SLNO (net +$345.5M) while four reduced holdings by -$139.4M. The…
INST-CLUSTER · Impact 4/10
May 28, 2026 SEC
Soleno Therapeutics filed Form 15-12G to terminate its SEC registration under Section 12(g) and suspend reporting…
15-12G · Impact 8/10
May 18, 2026 Insider
Anish Bhatnagar disposed of 131,400 shares
CHIEF EXECUTIVE OFFICER
May 18, 2026 Insider
Anish Bhatnagar disposed of 115,600 shares
CHIEF EXECUTIVE OFFICER
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 13, 2026
Clinical Trial
Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome
Phase 3 · COMPLETED
Sep 2, 2026
Press release
Kuehn Law Encourages Investors of Soleno Therapeutics, Inc. to Contact Law Firm
NEW YORK, Sept. 2, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors…
Aug 6, 2026
Earnings date
SLNO Q2 2026 Earnings Scheduled, 2026-08-06
May 14, 2026
Short interest
FTD: SLNO, 34,067 shares ($1.8M) failed to deliver
Settlement: 20260514, Price: $52.95, FTD Value: $1,803,847.65, SOLENO THERAPEUTICS INC COM PA
May 13, 2026
Short interest
FTD: SLNO, 9,562 shares ($0.5M) failed to deliver
Settlement: 20260513, Price: $52.93, FTD Value: $506,116.66, SOLENO THERAPEUTICS INC COM PA

SecBot reports

10 filings · 4 bullish · 3 bearish · 1 mixed · 2 neutral
All SLNO filing & press-release reports (10)